Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; A case of FVIII, FVIIa and G-CSF

Expert Opinion on Drug Delivery

Volumn 7, Issue 2, 2010, Pages 187-201

  Yatuv, Rivka ^a   Robinson, Micah ^a   Dayan, Inbal ^a   Baru, Moshe ^a  

^a Omri Laboratories Ltd   (Israel)

Author keywords

Factor VIIa; Factor VIII; G CSF; PEGylated liposomes; Pharmacodynamics; Therapeutic proteins

Indexed keywords

ALBINTERFERON ALPHA2B; ASPARAGINASE MACROGOL; BETA1A INTERFERON; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; CERTOLIZUMAB PEGOL; CHOLINESTERASE; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; DOXORUBICIN; ETANERCEPT; HEMOGLOBIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INTERLEUKIN 2; LIPOSOME; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGADEMASE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGVISOMANT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZALBIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SUBSTITUTION; ANXIETY; BLEEDING DISORDER; BLOOD PRESSURE; BREAST CANCER; CLINICAL TRIAL; DRUG CONJUGATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ENCAPSULATION; HEMOPHILIA A; HEPATITIS C; HUMAN; HYPEREMIA; KAPOSI SARCOMA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PROTEIN BINDING; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; SIDE EFFECT;

ANIMALS; ANTICOAGULANTS; CHEMISTRY, PHARMACEUTICAL; DRUG EVALUATION; DRUG EVALUATION, PRECLINICAL; FACTOR VIIA; FACTOR VIII; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LIPOSOMES; MODELS, BIOLOGICAL; MODELS, MOLECULAR; POLYETHYLENE GLYCOLS; PROTEINS;

EID: 76149134362     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903463846     Document Type: Review

References (110)

1. Banga AK. Therapeutic peptides and proteins: formulation, processing, and delivery systems. 2nd edition. Boca Raton, FL: CRC/Taylor & Francis; 2006
2. Gomez-Orellana I. Strategies to improve oral drug bioavailability. Expert Opin Drug Deliv 2005;2(3):419-433
3. Schuetz YB, Naik A, Guy RH, et al. Emerging strategies for the transdermal delivery of peptide and protein drugs. Expert Opin Drug Deliv 2005;2(3):533-548
4. Siekmeier R, Scheuch G. Systemic treatment by inhalation of macromolecules-principles, problems, and examples. J Physiol Pharmacol 2008;59:(Suppl 6):53-79
5. Stolnik S, Shakesheff K. Formulations for delivery of therapeutic proteins. Biotechnol Lett 2009;31(1):1-11
6. Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 2009;6(1):1-16
7. Khandare J, Minko T. Polymer-drug conjugates: progress in polymeric prodrugs. Prog Polym Sci 2006;31:359-397
8. Ryan SM, Mantovani G, Wang X, et al. Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin Drug Deliv 2008;5(4):371-383
9. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40(7):539-551
10. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003;2(3):214-221
11. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly (ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003;55(10):1261-1277
12. Basu A, Yang K, Wang M, et al. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug Chem 2006;17(3):618-630
13. De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol 2007;28(11):482-490
14. Hershfield MS, Buckley RH, Greenberg ML, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 1987;316(10):589-596
15. Chakravarti VS, Borns P, Lobell J, et al. Chondroosseous dysplasia in severe combined immunodeficiency due to adenosine deaminase deficiency (chondroosseous dysplasia in ADA deficiency SCID). Pediatr Radiol 1991;21(6):447-448
16. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002;99(6):1986-1994 (Pubitemid 34525479)
17. Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 2003;55(10):1293-1302
18. Chilukuri N, Sun W, Parikh K, et al. A repeated injection of polyethyleneglycol-conjugated recombinant human butyrylcholinesterase elicits immune response in mice. Toxicol Appl Pharmacol 2008;231(3):423-429
19. Pepinsky RB, LePage DJ, Gill A, et al. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther 2001;297(3):1059-1066
20. Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002;99(7):2599-2602
21. Moss J, Rosholm A, Laurén A. Safety and pharmacokinetics of a long-acting glycopegylated rFVIIa derivative: a first human dose trial in healthy subjects. J Thromb Haemost 2009;7:OC-WE-055
22. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002;54(4):459-476
23. Hirsch IB. Insulin analogues. N Engl J Med 2005;352(2):174-183
24. Sheldon B, Russell-Jones D, Wright J. Insulin analogues: an example of applied medical science. Diabetes Obes Metab 2009;11(1):5-19
25. Macdougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001;16:(Suppl 3):14-21
26. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84:(Suppl 1):3-10
27. Allen GA, Persson E, Campbell RA, et al. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 2007;27(3):683-689
28. Sorensen B, Persson E, Ingerslev J. Factor VIIa analogue (V158D/E296V/ M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol 2007;137(2):158-165
29. Brophy DF, Martin EJ, Nolte ME, et al. Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients. Haemophilia 2007;13(5):533-541
30. Liu T, Zhang X, Pan J, et al. Enhanced and prolonged efficacy of a novel recombinant FVIIa variant (BAY86-6150) for acute and prophylactic treatments in hemophilia A (HemA) mice. J Thromb Haemost 2009;7(2):OC-WE-057
31. Pan J, Kim J, Zhu D, et al. Binding to activated platelets and enhanced clotting properties of the recombinant FVIIa analogue Bay7. J Thromb Haemost 2009;7(2):OC-WE-059
32. Sytkowski AJ, Lunn ED, Risinger MA, et al. An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J Biol Chem 1999;274(35):24773-24778
33. Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008;9:52
34. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008;132(3):171-183
35. Rustgi VK. Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin 2009;25(4):991-1002
36. Gao Z, Bai G, Chen J, et al. Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris. Biosci Biotechnol Biochem 2009;73(3):688-694
37. Schmidt SR. Fusion-proteins as biopharmaceuticals-applications and challenges. Curr Opin Drug Discov Devel 2009;12(2):284-295
38. Zhao HL, Xue C, Wang Y, et al. Elimination of the free sulfhydryl group in the human serum albumin (HSA) moiety of human interferon-alpha2b and HSA fusion protein increases its stability against mechanical and thermal stresses. Eur J Pharm Biopharm 2009;72(2):405-411
39. Sheffield WP, Mamdani A, Hortelano G, et al. Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. Br J Haematol 2004;126(4):565-573
40. Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol 2009;86(3):215-223
41. Paukner S, Stiedl T, Kudela P, et al. Bacterial ghosts as a novel advanced targeting system for drug and DNA delivery. Expert Opin Drug Deliv 2006;3(1):11-22
42. Rossi L, Serafini S, Pierige F, et al. Erythrocyte-based drug delivery. Expert Opin Drug Deliv 2005;2(2):311-322
43. Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist 2008;13(3):248-260
44. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46(12 Pt 1):6387-6392
45. Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002;4(3):95-99
46. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003;42(5):419-436
47. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 2006;1(3):297-315
48. Brandl M, Gregoriadis G. Entrapment of haemoglobin into liposomes by the dehydration-rehydration method: vesicle characterization and in vivo behaviour. Biochim Biophys Acta 1994;1196(1):65-75
49. Kim JY, Kim JK, Park JS, et al. The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials 2009;30(29):5751-5756
50. Kedar E, Braun E, Rutkowski Y, et al. Delivery of cytokines by liposomes. II. Interleukin-2 encapsulated in long-circulating sterically stabilized liposomes: immunomodulatory and anti-tumor activity in mice. J Immunother Emphasis Tumor Immunol 1994;16(2):115-124 (Pubitemid 24303422)
51. Kedar E, Gur H, Babai I, et al. Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes. J Immunother 2000;23(1):131-145
52. Debs RJ, Fuchs HJ, Philip R, et al. Immunomodulatory and toxic effects of free and liposome-encapsulated tumor necrosis factor alpha in rats. Cancer Res 1990;50(2):375-380
53. Walde P, Ichikawa S. Enzymes inside lipid vesicles: preparation, reactivity and applications. Biomol Eng 2001;18(4):143-177
54. Colletier JP, Chaize B, Winterhalter M, et al. Protein encapsulation in liposomes: efficiency depends on interactions between protein and phospholipid bilayer. BMC Biotechnol 2002;2:9
55. Kirby CJ, Gregoriadis G. Preparation of liposomes containing factor VIII for oral treatment of haemophilia. J Microencapsul 1984;1(1):33-45
56. Tiukinhoy-Laing SD, Huang S, Klegerman M, et al. Ultrasound-facilitated thrombolysis using tissue-plasminogen activator-loaded echogenic liposomes. Thromb Res 2007;119(6):777-784
57. Adrian G, Huang L. Entrapment of proteins in phosphatidylcholine vesicles. Biochemistry 1979;18(25):5610-5614
58. Kedar E, Rutkowski Y, Braun E, et al. Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes. J Immunother Emphasis Tumor Immunol 1994;16(1):47-59 (Pubitemid 24216195)
59. Elbayoumi TA, Torchilin VP. Liposomes for targeted delivery of antithrombotic drugs. Expert Opin Drug Deliv 2008;5(11):1185-1198
60. Baru M, Carmel-Goren L, Barenholz Y, et al. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thromb Haemost 2005;93(6):1061-1068
61. Dayan I, Robinson M, Baru M. Enhancement of haemostatic efficacy of plasma-derived FVIII by formulation with PEGylated liposomes. Haemophilia 2009;15(5):1006-1013
62. Yatuv R, Dayan I, Carmel-Goren L, et al. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes. Haemophilia 2008;14(3):476-483
63. Klibanov AL, Maruyama K, Torchilin VP, et al. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990;268(1):235-237
64. Gabizon AA, Barenholz Y, Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 1993;10(5):703-708
65. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54(4):987-992
66. Yatuv R, Carmel-Goren L, Dayan I, et al. Binding of proteins to PEGylated liposomes and improvement of G-CSF efficacy in mobilization of hematopoietic stem cells. J Control Release 2009;135(1):44-50
67. Kaufman RJ, Anthonorakis SE, Fay PJ. Hemostasis and thrombosis: basic principles and clinical practice. 4th edition. Philadelphia: Lippincott Williams & Wilkins; 2001
68. Roosendaal G, Mauser-Bunschoten EP, De Kleijn P, et al. Synovium in haemophilic arthropathy. Haemophilia 1998;4(4):502-505
69. Hoots WK, Nugent DJ. Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost 2006;96(4):433-440
70. Fijnvandraat K, Berntorp E, ten Cate JW, et al. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost 1997;77(2):298-302
71. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 1977;60(2):390-404
72. Saenko EL, Ananyeva NM, Moayeri M, et al. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A. Curr Gene Ther 2003;3(1):27-41
73. Saenko EL, Pipe SW. Strategies towards a longer acting factor VIII. Haemophilia 2006;12:(Suppl 3):42-51
74. Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA 1997;94(22):11851-11856
75. Gale AJ, Pellequer JL. An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa. J Thromb Haemost 2003;1(9):1966-1971
76. Gale AJ, Radtke KP, Cunningham MA, et al. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. J Thromb Haemost 2006;4(6):1315-1322
77. Murphy JE, Pan C, Barnett T, et al. Site-specific PEGylation of rFVIII results in prolonged in vivo efficacy. J Thromb Haemost 2007;5(2):P-T-022
78. Regan LM, Jiang X, Ramsey P, et al. Biological activity of PEGylated factor VIII. J Thromb Haemost 2007;5(2):P-T-026
79. Tang L, Pan C, Atwal H, et al. PEGylation protects factor VIII from the inhibition of antibody inhibitors. J Thromb Haemost 2007;5(2):P-T-036
80. Spira J, Plyushch OP, Andreeva TA, et al. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood 2006;108(12):3668-3673
81. Spira J, Plyushch OP, Andreeva TA, et al. Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A. Thromb Haemost 2008;100(3):429-434
82. Powell JS, Nugent DJ, Harrison JA, et al. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost 2008;6(2):277-283
83. Martinowitz U, Lalezari S, Luboshitz J, et al. Infusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia A. Haemophilia 2008;14(5):1122-1124
84. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 2005;216(2-3):106-121
85. Available from: http://clinicaltrials.gov/ ct2/show/NCT00623727. [Last accessed November 2009]
86. Mathew P. Current opinion on inhibitor treatment options. Semin Hematol 2006;43(2 Suppl 4):S8-13
87. Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998;4(6):790-798
88. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost 2000;26(4):425-432
89. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994;55(6):638-648
90. Fridberg MJ, Hedner U, Roberts HR, et al. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagul Fibrinolysis 2005;16(4):259-266
91. Ingerslev J, Thykjaer H, Kudsk Jensen O, et al. Home treatment with recombinant activated factor VII: results from one centre. Blood Coagul Fibrinolysis 1998;9:(Suppl 1):S107-10
92. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998;80(6):912-918
93. Stennicke HR, Ostergaard H, Bayer RJ, et al. Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives. Thromb Haemost 2008;100(5):920-928
94. Schulte S. Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa. Thromb Res 2008;122:(Suppl 4):S14-19
95. Baru M, Spira J, Plyushch OP, et al. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in hemophilia A patients with inhibitors to factor VIII. J Thromb Haemost 2009;7(2):PP-WE-608
96. Roberts AW. G-CSF: a key regulator of neutrophil production, but that's not all! Growth Factors 2005;23(1):33-41
97. Anderlini P, Korbling M. The use of mobilized peripheral blood stem cells from normal donors for allografting. Stem Cells 1997;15(1):9-17 (Pubitemid 27057076)
98. Jansen J, Hanks S, Thompson JM, et al. Transplantation of hematopoietic stem cells from the peripheral blood. J Cell Mol Med 2005;9(1):37-50
99. Layton JE, Hockman H, Sheridan WP, et al. Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood 1989;74(4):1303-1307
100. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24(19):3187-3205
101. Anderlini P, Przepiorka D, Seong C, et al. Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion 1997;37(5):507-512
102. Holm M. Not all healthy donors mobilize hematopoietic progenitor cells sufficiently after G-CSF administration to allow for subsequent CD34 purification of the leukapheresis product. J Hematother 1998;7(2):111-113
103. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995;85(2):588-596
104. Stiff P, Gingrich R, Luger S, et al. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 2000;26(5):471-481
105. Constantinescu I, Levin E, Gyongyossy-Issa M. Liposomes and blood cells: a flow cytometric study. Artif Cells Blood Substit Immobil Biotechnol 2003;31(4):395-424
106. Ahmad SS, Scandura JM, Walsh PN. Structural and functional characterization of platelet receptor-mediated factor VIII binding. J Biol Chem 2000;275(17):13071-13081
107. Dahlback B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med 2005;257(3):209-223
108. Hedner U. Mechanism of action of factor VIIa in the treatment of coagulopathies. Semin Thromb Hemost 2006;32:(Suppl 1):77-85
109. High KA. The leak stops here: platelets as delivery vehicles for coagulation factors. J Clin Invest 2006;116(7):1840-1842
110. Raut S, Di Giambattista M, Bevan SA, et al. Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation. Thromb Haemost 1998;80(4):624-631